Open access
Aug 2026
Targeting ABL kinases overcomes melanoma immune evasion following resistance to MAPK inhibition
MAPK inhibitors (MAPKi) are important treatment options for some patients with metastatic melanoma; however, resistance inevitably develops in the vast majority of cases (>70%). Here, using immune-proficient mouse models, single-cell RNA sequencing, flow cytometry, and datasets from patients treated with MAPKi, we demo...
Rakshamani Tripathi, B. Kalal, Shirin Soni et al.
· Nature Communications · 0 citations